Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases

Darson, Micheal F.; Pacelli, Anna; Roche, Patrick C.; Rittenhouse, Harry G.; Wolfert, Robert L.; Saeid, Mohammad S; Young, Charles Y.F.; Klee, George G.; Tindall, Donald J.; Bostwick, David G.

doi:10.1016/s0090-4295(98)00637-2

Cited by 109 publications

(50 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…They found more intense hK2-specific immunostaining in lymphatic metastases and in high-grade tumors compared with well-differentiated tumors and benign tissue, whereas contrary findings were reported for PSA (8 ). Herrala et al quantified expression by a conceptually different approach; in situ hybridization revealed that hK2 was expressed at higher concentrations in PCa tissue compared with benign prostate tissue (P Ͻ0.0005), (10 ).…”

Section: Discussionmentioning

confidence: 93%

Comparison of Free and Total Forms of Serum Human Kallikrein 2 and Prostate-Specific Antigen for Prediction of Locally Advanced and Recurrent Prostate Cancer

et al. 2007

View full text Add to dashboard Cite

Background:We evaluated the association of total and free forms of serum human kallikrein 2 (hK2) and prostate-specific antigen (PSA) with prostate cancers of unfavorable prognosis. Methods: We retrospectively measured total PSA (tPSA), free PSA (fPSA), and total hK2 (thK2) in preoperative serum samples from 867 men [and assessed free hK2 (fhK2) measured in 577 of these men] treated with radical prostatectomy for clinically localized prostate cancer. Associations between biomarker concentrations and extracapsular extension, seminal vesicle invasion, and biochemical recurrence (BCR) were evaluated. A subset of patients with PSA <10 g/L, the group most commonly seen in clinical practice in the US, was analyzed. Results: thK2 was the strongest predictor of extracapsular extension and seminal vesicle invasion (areas under the ROC curve [AUC], 0.662 and 0.719, respectively), followed by tPSA (AUC, 0.654 and 0.663). All biomarkers were significant predictors of BCR. hK2 forms, but not PSA forms, remained highly significant for predicting BCR in the low-PSA group. Combining tPSA, fPSA,

show abstract

Section: Discussionmentioning

confidence: 93%

Comparison of Free and Total Forms of Serum Human Kallikrein 2 and Prostate-Specific Antigen for Prediction of Locally Advanced and Recurrent Prostate Cancer

et al. 2007

View full text Add to dashboard Cite

show abstract

“…However, low KLK3 expression in tumoral tissues may be associated with the development of more aggressive tumors (Stege et al, 2000), while others have found no differences in KLK3 gene expression in prostate cancer and BPH tissues (Henttu et al, 1990). Larger concentrations of PSA have been observed in tumor tissues compared to BPH tissues, based on immunohistochemical analyzes using monoclonal and polyclonal antibodies (Darson et al, 1999).…”

Section: Discussionmentioning

confidence: 99%

Differential expression of the KLK2 and KLK3 genes in peripheral blood and tissues of patients with prostate cancer

et al. 2006

View full text Add to dashboard Cite

We used the multiplex semi-quantitative reverse-transcriptase PCR (RT-PCR) to investigate kallikrein 2 and 3 (KLK2 and KLK3) mRNA levels in prostate tissue from 42 prostate cancer patients, 33 of whom were also assessed for peripheral blood KLK2 expression by qualitative semi-nested RT-PCR. We found that KLK2 was an important tissue biomarker for distinguishing between prostate cancer patients and those with benign prostatic hyperplasia, particularly when KLK2 expression was > 60% of that of the β2-microglobulin constitutive gene. Patients with an average relative expression value ≥ 0.6 (cutoff value) had an eleven-fold higher chance of having prostate cancer. When one or two tissues samples were evaluated for KLK2 expression using the cutoff value the estimated chance of having prostate cancer was increased by seven times for one positive sample and 45 times for two positive samples. There was no significant correlation between KLK3 gene expression and prostate cancer diagnosis. Logistic regression for blood and tissue KLK2 expression successfully detected 92% of the prostate cancer cases. The detection of KLK2 in blood showed a sensitivity of 59% and a specificity of 82%. This study indicates that the KLK2 gene may be a useful molecular marker for the diagnosis of prostate cancer and that analysis of KLK2 expression in blood and tissues could provide a novel approach for the clinical investigation of this type of cancer.

show abstract

“…In these glands, basal cells can be identified, though this lesion should be distinguished from HGPIN since it appears to be a late event in prostate gland carcinogenesis and warrants immediate therapy. PIN lesions do not contribute to an elevation of serum PSA, PSA density, or a decrease in the free-to-total PSA ratio (Alexander et al, 1996;Darson et al, 1999;Ronnett et al, 1993). PIN lesions show less expression of PSA in luminal cells, as determined by immunohistochemistry, than do benign epithelial glands (Ronnett et al, 1993;Alexander et al, 1996).…”

Section: Differential Diagnosis Of Pinmentioning

confidence: 97%

Prostate Cancer Precursor Diseases

Papatsoris¹,

Kostopoulos²,

Migdalis³

et al. 2012

Intraepithelial Neoplasia

View full text Add to dashboard Cite

Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases

Cited by 109 publications

References 21 publications

Comparison of Free and Total Forms of Serum Human Kallikrein 2 and Prostate-Specific Antigen for Prediction of Locally Advanced and Recurrent Prostate Cancer

Comparison of Free and Total Forms of Serum Human Kallikrein 2 and Prostate-Specific Antigen for Prediction of Locally Advanced and Recurrent Prostate Cancer

Differential expression of the KLK2 and KLK3 genes in peripheral blood and tissues of patients with prostate cancer

Prostate Cancer Precursor Diseases

Contact Info

Product

Resources

About